Rozai-Dorfmann病市場 - 全球產業規模、佔有率、趨勢、機會、預測：按類型、治療類型、最終用戶、地區和競爭格局分類，2021-2031年

全球羅札伊-多夫曼病 (RDD) 市場預計將從 2025 年的 5,331.2 億美元成長到 2031 年的 7,722.2 億美元，複合年成長率為 6.37%。

RDD是一種罕見的非朗格漢斯細胞組織細胞增生症，其特徵是組織細胞良性增殖和聚集，常表現為明顯的無痛性頸部淋巴結腫大，並可能涉及皮膚和骨骼等其他部位。市場成長主要得益於RDD被重新歸類為腫瘤性疾病以及精準醫療的相應進步。基因組分析技術的改進揭示了特定的分子標靶，加速了激酶抑制劑的仿單標示外使用和研發。例如，組織細胞增生症協會在2024年報告稱，50%的RDD病例中發現了MAP激酶路徑中的致癌性基因突變，這支持了標靶治療的趨勢。

然而，RDD臨床病程難以預測且常有自發性緩解，這是市場成長的主要障礙。許多確診患者無症狀或病情可自發性消退，在許多情況下，僅需後續觀察而非藥物治療。這種自發性病程限制了強化治療的商業性潛力，也使得招募病患參與新藥認證所需的大規模臨床試驗變得困難。

市場促進因素

全球羅扎伊-多夫曼病 (RDD) 市場的主要驅動力是臨床開發平臺的擴展。這加深了我們對 RDD 多種病理生理機制的理解，並加速了創新治療方法的發展。這種研究動能對於連結基礎科學和臨床實踐至關重要，尤其是在長期患者數據有限的罕見疾病領域。非營利組織在降低早期研究風險和提供資金以吸引製藥公司方面發揮著至關重要的作用。例如，組織細胞增生症協會在 2024 年年度報告（2024 年 11 月）中指出，該協會已在全球範圍內提供了 202 項研究津貼，為未來的臨床進展奠定了堅實的基礎。這種持續的資金支持有助於建立國際患者登記系統和進行臨床試驗，這對於在小規模患者群體中檢驗新治療方法至關重要。

同時，由於診斷率的提高，以及人們對該疾病的認知增強，患者群體也不斷擴大。目前的診斷方法優先識別結外症狀和複雜的臨床關聯，這些症狀和關聯先前常常被忽視或誤診為其他發炎性疾病。 2024年5月發表於ASCO Post的一篇報導指出，10%的RDD病例合併免疫疾病，凸顯了全面診斷評估的必要性。準確識別這些合併症有助於應用合適的標靶治療，從而促進其商業性化應用。 Exelisys公司2024年度報告（2025年2月發布）也反映了這一點，報告指出，MEK抑制劑Cobimetinib在美國以外的淨銷售額產生了300萬美元的特許權使用費，表明市場對該治療領域持續保持著濃厚的興趣。

市場挑戰

由於羅札伊-多夫曼氏症（Rozai-Dorfmann disease，RDD）的臨床病程難以預測且自發性緩解率高，全球RDD市場面臨許多限制因素。阻礙收入成長的主要障礙在於，相當一部分確診患者的RDD症狀會自發性緩解，通常無需藥物治療即可改善。這自然抑制了商業性對積極治療的需求，因為臨床醫生往往選擇後續觀察而非處方昂貴的激酶抑制劑或免疫療法。因此，這些治療方法的適用人群僅限於病情最嚴重或難治性病例，從而削弱了製造商積極推廣新治療方法的經濟動力。

此外，這種自然病程進展阻礙了臨床研發，而臨床研發對於市場擴張至關重要。鑑於許多患者無需積極治療，製藥公司在招募適合大規模研究的受試者方面面臨相當大的挑戰。加拿大組織細胞增生症協會在2024年報告稱，70%至80%的RDD患者無需醫療干預即可出現症狀自發性改善。如此高的自發性緩解率使得在自發性緩解的背景下證明新藥的統計學療效變得複雜，導致監管核准延遲，並阻礙了整體市場擴張。

市場趨勢

羅札伊-多夫曼病 (RDD)商業性格局的一個顯著新趨勢是監管機構日益重視孤兒藥認定和獎勵。這有助於降低開發這種極為罕見疾病治療方法的風險。監管機構正擴大提供快速核准流程和經濟激勵措施，以鼓勵製藥公司投資於先前被認為經濟上不可行、患病率低的疾病的治療方法。鑑於 RDD 患者群體規模小，且缺乏大規模重磅藥物的前景，這種支持性環境對 RDD 尤其重要。這一趨勢也體現在整個產業轉向罕見疾病產品組合的轉變。例如，Fierce Pharma 在 2026 年 1 月的報告中指出，2025 年 FDA核准的46 種新藥中，有 26 種（佔總數的 57%）是針對罕見疾病或罕見疾病療法的，這表明製藥業擁有強大的研發管線，專注於組織細胞增生性疾病等特殊疾病。

同時，次世代定序（NGS）在精準診斷中的廣泛應用正在革新復發性疾病（RDD）的臨床管理，推動市場從廣譜化療轉向基於基因組資訊的個人化治療方案。隨著醫療專業人員越來越發現RDD與特定激酶突變之間的關聯，全面的基因組分析以識別可治療標靶正逐漸成為標準做法。這些技術的整合使得標靶抑制劑在抗藥性病例中能夠有效進行仿單標示外使用，與傳統治療方法相比，顯著改善患者的預後。美國國立衛生研究院（NIH）於2025年1月發布的關於次世代定序臨床應用的報告強調了該方法的臨床效用，報告顯示，接受NGS治療的複雜腫瘤患者中有37.5%達到了部分緩解。這凸顯了分子診斷在製定有效治療策略方面的重要性日益凸顯。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球羅札伊-多夫曼病市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 類型（經典型（淋巴結型）Rozay-Dorfmann病，淋巴結外型Rozay-Dorfmann病）
  • 治療類型（診斷、治療）
  • 依最終使用者（醫院/診所、門診中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美羅札伊-多夫曼病市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲羅札伊-多夫曼病市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區羅扎伊-多夫曼病市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲羅扎伊病和多夫曼病市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲羅札伊-多夫曼病市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球羅札伊-多夫曼病市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Teva Pharmaceuticals Ltd.
• Zydus Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries Ltd.
• Advanz Pharmaceuticals
• Novartis AG
• Mylan NV
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Ltd.
• Viatris Inc.
• Pfizer Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The global Rosai-Dorfman Disease (RDD) market is projected to expand from USD 533.12 billion in 2025 to USD 772.22 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 6.37%. RDD is a rare, non-Langerhans cell histiocytosis marked by the benign proliferation and accumulation of histiocytes, often presenting as significant, painless cervical lymph node enlargement and potentially affecting other areas like the skin and bones. The market's growth is largely fueled by RDD's reclassification as a neoplastic disorder and the subsequent progress in precision medicine. Improved genomic profiling has uncovered specific molecular targets, promoting the off-label application and creation of kinase inhibitors. For instance, the Histiocytosis Association reported in 2024 that cancer-causing genetic mutations in the MAP kinase pathway were found in 50% of RDD cases, supporting a move towards targeted treatments.

However, a major obstacle to market growth is RDD's unpredictable clinical progression and frequent spontaneous remission. Many diagnosed individuals are asymptomatic or experience a self-resolving form of the disease, often requiring only monitoring instead of drug treatments. This natural course restricts the commercial potential for intensive therapies and complicates efforts to enroll patients in the extensive clinical trials needed for new drug approvals.

Market Driver

A key driver for the global Rosai-Dorfman Disease market is the expanding clinical research and development pipeline, which enhances our understanding of RDD's diverse pathology and accelerates innovative therapies. This research momentum is crucial for rare diseases, bridging foundational science with clinical practice, especially where long-term patient data has been limited. Non-profit organizations are vital, offering funding to reduce risks in early-stage studies and attract pharmaceutical companies. For instance, the Histiocytosis Association reported in its '2024 Annual Report' (November 2024) that it has provided 202 research grants globally, establishing a strong base for future clinical advancements. This consistent financial support helps create international registries and trials, essential for validating new treatments in a small patient population.

Simultaneously, increasing diagnosis rates, driven by better disease recognition, are expanding the patient pool. Current diagnostic approaches prioritize identifying extranodal symptoms and intricate clinical links, often previously overlooked or mistaken for other inflammatory conditions. The ASCO Post highlighted in May 2024 that RDD co-occurs with an immunologic disease in 10% of cases, emphasizing the need for thorough diagnostic evaluations. Precise identification of these co-existing conditions enables the use of appropriate targeted therapies, boosting their commercial adoption. Reflecting this, Exelixis's '2024 Annual Report' (February 2025) noted that ex-U.S. net sales of the MEK inhibitor cobimetinib generated $3.0 million in royalties, demonstrating the continued market interest in treatments within this therapeutic class.

Market Challenge

The global Rosai-Dorfman Disease market faces significant constraints due to the disease's unpredictable clinical progression and high rate of spontaneous remission. A key barrier to revenue growth is that a substantial portion of diagnosed individuals experience a self-resolving form of RDD, which often improves without drug intervention. This naturally curtails the commercial demand for aggressive treatments, as clinicians frequently choose observation over prescribing expensive kinase inhibitors or immunotherapies. Consequently, the eligible patient population for such therapies is limited to only the most severe or resistant cases, thereby reducing the financial motivation for manufacturers to vigorously promote new treatments.

Furthermore, this natural history impedes the clinical development crucial for market advancement. Pharmaceutical companies encounter considerable challenges in recruiting suitable participants for extensive studies, given that many patients do not need active treatment. The Histiocytosis Association of Canada reported in 2024 that 70% to 80% of RDD patients show spontaneous symptom improvement without medical intervention. This high rate of natural recovery complicates efforts to prove the statistical effectiveness of new drugs against a backdrop of natural remission, leading to delays in regulatory approvals and hindering overall market expansion.

Market Trends

An emerging trend significantly influencing the Rosai-Dorfman Disease (RDD) commercial landscape is the increasing regulatory emphasis on Orphan Drug Designations and incentives, which reduces the development risks for therapies targeting this extremely rare condition. Regulatory authorities are increasingly offering accelerated pathways and financial advantages to encourage pharmaceutical companies to invest in treatments for low-prevalence diseases, previously deemed economically unfeasible. This supportive climate is particularly vital for RDD, given its small patient population where large-scale blockbuster drugs are improbable. This trend is mirrored by a broader industry pivot towards rare disease portfolios; for example, Fierce Pharma reported in January 2026 that 26 of the FDA's 46 novel drug approvals in 2025 (57% of the total) were for rare diseases or orphan treatments, indicating a strong pipeline favoring specialized conditions like histiocytic disorders.

Concurrently, the extensive adoption of Next-Generation Sequencing (NGS) for precision diagnosis is revolutionizing RDD clinical management, shifting the market from broad-spectrum chemotherapy towards personalized, genomically guided treatment plans. As healthcare professionals increasingly identify the link between RDD and specific kinase mutations, comprehensive genomic profiling is becoming standard practice to pinpoint treatable targets. This integration of technology enables the effective off-label application of targeted inhibitors for resistant cases, yielding considerably better patient outcomes than traditional regimens. The National Institutes of Health's January 2025 report on 'Clinical implementation of next-generation sequencing testing' highlighted the clinical utility of this method, showing that 37.5% of patients with complex neoplasms receiving NGS-guided therapy achieved a partial response, affirming the growing dependence on molecular diagnostics to formulate effective treatment strategies.

Key Market Players

• Teva Pharmaceuticals Ltd.
• Zydus Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries Ltd.
• Advanz Pharmaceuticals
• Novartis AG
• Mylan N.V.
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Ltd.
• Viatris Inc.
• Pfizer Inc.

Report Scope

In this report, the Global Rosai-Dorfman Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rosai-Dorfman Disease Market, By Type

• Classic (nodal) Rosai-Dorfman disease
• Extranodal Rosai-Dorfman disease

Rosai-Dorfman Disease Market, By Procedure Type

• Diagnosis
• Treatment

Rosai-Dorfman Disease Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Rosai-Dorfman Disease Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rosai-Dorfman Disease Market.

Available Customizations:

Global Rosai-Dorfman Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rosai-Dorfman Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Classic (nodal) Rosai-Dorfman disease, Extranodal Rosai-Dorfman disease)
  • 5.2.2. By Procedure Type (Diagnosis, Treatment)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Rosai-Dorfman Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Procedure Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Rosai-Dorfman Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Procedure Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Rosai-Dorfman Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Procedure Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Rosai-Dorfman Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Procedure Type
      • 6.3.3.2.3. By End User

7. Europe Rosai-Dorfman Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Procedure Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Rosai-Dorfman Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Procedure Type
      • 7.3.1.2.3. By End User
  • 7.3.2. France Rosai-Dorfman Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Procedure Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Rosai-Dorfman Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Procedure Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Rosai-Dorfman Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Procedure Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Rosai-Dorfman Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Procedure Type
      • 7.3.5.2.3. By End User

8. Asia Pacific Rosai-Dorfman Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Procedure Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Rosai-Dorfman Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Procedure Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Rosai-Dorfman Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Procedure Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Rosai-Dorfman Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Procedure Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Rosai-Dorfman Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Procedure Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Rosai-Dorfman Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Procedure Type
      • 8.3.5.2.3. By End User

9. Middle East & Africa Rosai-Dorfman Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Procedure Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Rosai-Dorfman Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Procedure Type
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Rosai-Dorfman Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Procedure Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Rosai-Dorfman Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Procedure Type
      • 9.3.3.2.3. By End User

10. South America Rosai-Dorfman Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Procedure Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Rosai-Dorfman Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Procedure Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Rosai-Dorfman Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Procedure Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Rosai-Dorfman Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Procedure Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Rosai-Dorfman Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Teva Pharmaceuticals Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Zydus Pharmaceuticals, Inc.
• 15.3. Sun Pharmaceutical Industries Ltd.
• 15.4. Advanz Pharmaceuticals
• 15.5. Novartis AG
• 15.6. Mylan N.V.
• 15.7. Aurobindo Pharma Limited
• 15.8. Dr. Reddy's Laboratories Ltd.
• 15.9. Viatris Inc.
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer